Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CancerVax Ends Development of Melanoma Vaccine Canvaxin

This article was originally published in The Pink Sheet Daily

Executive Summary

CancerVax is dropping development of its cancer vaccine Canvaxin after a data safety monitoring board concludes a Phase III trial in stage III melanoma will not show a survival benefit.
Advertisement

Related Content

Dendreon Submits Rolling BLA For Provenge Prostate Cancer Vaccine
Dendreon Submits Rolling BLA For Provenge Prostate Cancer Vaccine
Antigenics Improves Oncophage Vaccine Manufacturing Output Ahead Of Registration Trial
Antigenics Improves Oncophage Vaccine Manufacturing Output Ahead Of Registration Trial
Dendreon Provenge Plant Completion Is Last Hurdle Before BLA Filing
Canvaxin Melanoma Vaccine BLA Delayed Until 2007 After Trial Fails
Canvaxin Melanoma Vaccine BLA Delayed Until 2007 After Trial Fails

Topics

Advertisement
UsernamePublicRestriction

Register

PS061204

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel